Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4130MR)

This product GTTS-WQ4130MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4130MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1995MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ6568MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ12835MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ7614MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ757MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ12633MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15873MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ8446MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW